Results 61 to 70 of about 98,010,213 (261)

Detection of breastmilk antibodies targeting SARS-CoV-2 nucleocapsid, spike and receptor-binding-domain antigens

Emerging Microbes and Infections, 2020
A 40-year-old female was found to have strongly neutralizing SARS-CoV-2 breastmilk IgA and IgG antibodies reactive against multiple SARS-CoV-2 antigens at 2.5 months after documented infection with SARS-CoV-2.
D. M. Favara, M. L. Ceron-Gutierrez, G. W. Carnell, J. L. Heeney, P. Corrie, R. Doffinger   +5 more
doaj   +1 more source

Antibody Response to SARS-CoV-2 among COVID-19 Confirmed Cases and Correlates with Neutralizing Assay in a Subgroup of Patients in Delhi National Capital Region, India

Vaccines, 2022
Background: The plaque reduction neutralization test (PRNT) is the gold standard to detect the neutralizing capacity of serum antibodies. Neutralizing antibodies confer protection against further infection.
Puneet Misra, Shashi Kant, Randeep Guleria, Sanjay K. Rai, Abhishek Jaiswal, Suprakash Mandal, Guruprasad R. Medigeshi, Mohammad Ahmad, Anisur Rahman, Meenu Sangral, Kapil Yadav, Mohan Bairwa, Partha Haldar, Parveen Kumar   +13 more
doaj   +1 more source

Potent neutralizing RBD‐specific antibody cocktail against SARS‐CoV‐2 and its mutant

MedComm, 2021
The ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its variants has posed a serious global public health emergency.
Lina Jia, Yan‐Ping Liu, Li‐Fei Tian, Chao Xiong, Xin Xu, Honge Qu, Weixi Xiong, Dong Zhou, Feng Wang, Zheng Liu, Xiao‐Xue Yan, Wenqing Xu, Lin Tang   +12 more
doaj   +1 more source

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition

Cell Reports, 2021
Summary: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages that are more transmissible and resistant to currently approved antibody therapies poses a considerable challenge to the clinical treatment of coronavirus ...
Kevin J. Kramer, Nicole V. Johnson, Andrea R. Shiakolas, Naveenchandra Suryadevara, Sivakumar Periasamy, Nagarajan Raju, Jazmean K. Williams, Daniel Wrapp, Seth J. Zost, Lauren M. Walker, Steven C. Wall, Clinton M. Holt, Ching-Lin Hsieh, Rachel E. Sutton, Ariana Paulo, Rachel S. Nargi, Edgar Davidson, Benjamin J. Doranz, James E. Crowe, Jr., Alexander Bukreyev, Robert H. Carnahan, Jason S. McLellan, Ivelin S. Georgiev   +22 more
doaj   +1 more source

Neutralizing antibodies for SARS-CoV-2 infection

Revista Española de Quimioterapia, 2022
The COVID-19 pandemic has boosted significant research in developing monoclonal antibodies (mAbs) to treat and prevent SARS-CoV-2 infection. Clinical trials have shown that mAbs are safe and effective in preventing hospitalization and death in patients with mild to moderate COVID-19 risk factors for progression.
openaire   +2 more sources

Monoclonal Antibodies to S and N SARS-CoV-2 Proteins as Probes to Assess Structural and Antigenic Properties of Coronaviruses

, 2021
Antibodies targeting the spike (S) and nucleocapsid (N) proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are essential tools. In addition to important roles in the treatment and diagnosis of infection, the availability of high ...
Alexandria Ostman, Rebecca J. Kaddis Maldonado, Malgorzata Sudol, Eunice C. Chen, Allen M. Minns, Neil D. Christensen, Rinki Kumar, Ruth H. Nissly, Natalie W. Buchkovich, Randall Rossi, Maria C. Bewley, Scott E. Lindner, Leslie J. Parent, John M. Flanagan, Meera Surendran Nair, Vivek Kapur, Abhinay Gontu, Nicholas J. Buchkovich, Suresh V. Kuchipudi   +18 more
core   +1 more source

Neutralizing antibodies against SARS-CoV-2

Uirusu, 2023
Severe acute respiratory syndrome (SARS) corona virus 2 (SARS-CoV-2) is a novel coronavirus that infects humans and causes respiratory symptoms, resulting in a global pandemic since its appearance in 2019. Neutralizing antibody production is an important immune response following SARS-CoV-2 infection, and a great deal of research has been performed ...
openaire   +2 more sources

SARS-CoV-2-specific anti-RBD IgG antibodies after prime and boost dose according to age.

, 2022
Data presented are SARS-CoV-2-specific anti-RBD IgG antibodies 28 days after prime dose, 14 days after first and second boost dose according to age (18–59 years and ≥60 years) in each regimen. Horizontal bars show geometric mean titer and error bars show
Lili Wang (104605), Jialu Feng (438878), Shihua Ma (12647443), Pan Du (54309), Cancan Chen (12647452), Xiaoyu Xu (356293), Xiling Guo (197353), Yin Chen (125855), Wei Chen (23863), Hongxing Pan (12647446), Lianpan Dai (553508), Pengfei Jin (1960690), Lairun Jin (12647449), Yanan Zhang (1322391), Fengcai Zhu (354575), Jingxian Liu (257255), Fengjuan Shi (6535796), George F. Gao (30860), Jingxin Li (486899)   +18 more
core   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain

Human Vaccines & Immunotherapeutics, 2022
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants have been reported to be resistant to several neutralizing antibodies (NAbs) targeting Receptor Binding Domain (RBD) and N Terminal Domain (NTD) of spike (S) protein and thus inducing ...
Xingsu Gao, Linlin Fan, Binyang Zheng, Haoze Li, Jiwei Wang, Li Zhang, Jingxin Li, Fengcai Zhu   +7 more
doaj   +1 more source